• Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax

  • 2024/12/26
  • 再生時間： 19 分
  • ポッドキャスト

Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In this week's episode, we'll be comparing BTK inhibitors in relapsed/refractory CLL. Then, we'll hear how researchers in the UK unraveled the genetic background of the AnWj blood group. Finally we'll learn about the role of BCL-2 and BAFF in CLL cell survival following venetoclax therapy.

    Featured Articles:

    • Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype
    • Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE
    • Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
    続きを読む 一部表示

あらすじ・解説

In this week's episode, we'll be comparing BTK inhibitors in relapsed/refractory CLL. Then, we'll hear how researchers in the UK unraveled the genetic background of the AnWj blood group. Finally we'll learn about the role of BCL-2 and BAFF in CLL cell survival following venetoclax therapy.

Featured Articles:

  • Deletions in the MAL gene result in loss of Mal protein, defining the rare inherited AnWj-negative blood group phenotype
  • Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE
  • Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia
続きを読む 一部表示

Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclaxに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。